drospirenone: Clinical Trials

18 trials of drospirenone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 2 recruiting, 1 terminated, 1 withdrawn. 18 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 118Completed 14, Recruiting 2, Terminated 1, Withdrawn 1
Phase 22Completed 1, Recruiting 1

Follow drospirenone: new trials by email Literature Review of drospirenone trials Research Report on drospirenone

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
pelabresib, repaglinide, midazolam - Advanced Malignancies
Phase 1RecruitingNovartis Pharmaceuticals242026-06-122026-10-09
A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)
HS-10374 tablets, Drospirenone and Ethinyl Estradiol tablets - Psoriasis (PsO)
Phase 1CompletedHansoh BioMedical R&D Company182025-05-282025-09-18
Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study
Drospirenone - Contraception
Phase 1 / Phase 2RecruitingChulalongkorn University162024-04-182026-03-19
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC) - Healthy Volunteers
Phase 1CompletedNewAmsterdam Pharma302024-02-052024-09-19
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
LY3437943, Ethinyl Estradiol, Drospirenone - Overweight
Phase 1CompletedEli Lilly and Company462023-09-122024-07-26
A Study of Milvexian in Healthy Adult Females
Milvexian, Midazolam, Ethinylestradiol - Healthy Female
Phase 1CompletedJanssen Pharmaceutica N.V., Belgium202023-01-252025-03-30
Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440
Drospirenone/Ethinylestradiol, Midazolam, JNJ-64530440 - Healthy
Phase 1WithdrawnJanssen Research & Development, LLC2021-06-012021-03-26
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
levonorgestrel/ Microlut, Norethindrone/ Noriday, Desogestrel/ Cerazette - Biological Availability
Phase 1CompletedBayer682017-11-292020-04-15
A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females
JNJ-64155806 150 mg, Ethinylestradiol/drospirenone 0.02 mg/3 mg, COCP Placebo - Healthy
Phase 1TerminatedJanssen Research & Development, LLC182017-04-132017-09-01
A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)
Drospirenone/Ethinylestradiol, Midazolam, JNJ-56136379 - Healthy
Phase 1CompletedJanssen Sciences Ireland UC182017-03-272017-09-06
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
15 mg E4/3 mg DRSP, 30 mcg EE/150 mcg LNG, 20 mcg EE/3 mg DRSP - Contraception, Liver Metabolism
Phase 1 / Phase 2CompletedEstetra1012016-09-012018-02-05
To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants
Drospirenone/ethinylestradiol, AL-335, Odalasvir (ODV) - Healthy
Phase 1CompletedJanssen Research & Development, LLC242016-08-012017-01-23
E4/DRSP Single and Multiple Dose PK and Early QT Study
15 mg E4/3 mg DRSP, 30 mg E4/6 mg DRSP, 60 mg E4/12 mg DRSP - Contraception
Phase 1CompletedEstetra552016-05-012017-04-21
Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate
EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo, EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid - Contraception
Phase 1CompletedBayer1722006-12-012013-09-20
Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)
EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300), EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca), L-5-MTHF 0.451mg (Metafolin) - Contraception
Phase 1CompletedBayer442006-10-012013-08-07
Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)
EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131), EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca), L-5-MTHF Ca 0.451 mg (Metafolin) - Contraception
Phase 1CompletedBayer482006-08-012013-08-07
Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ® - Healthy
Phase 1CompletedTeva Pharmaceuticals USA332006-07-012010-12-08
Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ® - Healthy
Phase 1CompletedTeva Pharmaceuticals USA322006-06-012010-12-08

Conditions studied

Obesity (2)  ·  Overweight (1)  ·  Psoriasis (1)

Sponsors

Bayer (4)  ·  Janssen Research & Development, LLC (3)  ·  Estetra (2)  ·  Teva Pharmaceuticals USA (2)  ·  Chulalongkorn University (1)  ·  Eli Lilly and Company (1)  ·  Hansoh BioMedical R&D Company (1)  ·  Janssen Pharmaceutica N.V., Belgium (1)  ·  Janssen Sciences Ireland UC (1)  ·  NewAmsterdam Pharma (1)  ·  Novartis Pharmaceuticals (1)

Countries

United States (7)  ·  Germany (3)  ·  Belgium (2)  ·  Netherlands (2)  ·  China (1)  ·  France (1)  ·  Italy (1)  ·  Spain (1)  ·  Thailand (1)

Top investigators

Anthony R Godfrey, Pharm.D. (2)  ·  Christine Klipping (1)  ·  Jeroen van de Wetering, MD (1)  ·  Kent A Swaine (1)  ·  Punyawee Utaipatanacheep (1)

Results publications

PMID 10560680, PMID 11245554, PMID 11433905, PMID 12841897, PMID 19461456, PMID 22067789, PMID 22909145, PMID 23610531, PMID 2449395, PMID 26232513, PMID 27467196, PMID 28433989, PMID 29634911, PMID 30347490, PMID 31493139, PMID 31758920, PMID 32202076, PMID 32312141, PMID 33008401, PMID 33547015, PMID 3450848, PMID 36103980, PMID 36316023, PMID 37544572, PMID 7068318, PMID 7500749, PMID 7500750, PMID 9673838

NIH funding

2005 (2), 2016 (2), 2017 (2), 2025 (1)